Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Quick Stats
Feb 02, 202662.5
AI Score
BUY0.16
Volume Ratio
Feb 11, 2026
Next Earnings
18
+ve Days (30d)
11
-ve Days (30d)
AVXL Stock Summary
Last updated
AVXL is currently trading at $4.505, positioned below its 200-day moving average of $7.88, suggesting bearish momentum. The stock has a 52-week range of $2.86 to $13.99.
Technical Analysis: The 50-day moving average stands at $4.19, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates AVXL at 62.5/100 with a BUY recommendation.
AVXL Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
AVXL Price vs Max Options Open Interest
AVXL Max Change In Options Open Interest
AVXL Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AVXL Daily Out of Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AVXL Daily In the Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AVXL Most Active Options by Volume(near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Anavex Life Sciences is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
AVXL Moving Averages Analysis
Anavex Life Sciences has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Feb 02, 2026
AVXL (Anavex Life Sciences) Simple Moving Averages
Moving Averages are last updated Feb 02, 2026
| Days | MA |
|---|---|
| 10 | 5.01 |
| 20 | 4.71 |
| 30 | 4.38 |
| 50 | 4.19 |
| 100 | 6.22 |
| 200 | 7.88 |
AVXL Fundamental Analysis
| P/E (Forward) | 3.8521 |
| P/E (Trailing) | -- |
| Market Cap ($) | 419.9 million |
| Earnings/Share ($) | -0.54 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.48 |
| EPS Estimate Next Year ($) | 1.27 |
| WallStreet Target Price ($) | 22 |
| Most Recent Quarter |
Anastanios Skarpelos took a risk to buy patents from Dr. Vamvakides, leading to the founding of Anavex. The company acquired the patents for a minimum investment of $1 million/year to develop a clinical program using the molecules. Tangi Maurice published research but never discovered new molecules.
Updated 2025-12-06 01:00:01